Researchers Identify Diagenode Kit as Industry-leading Solution for Studying Global DNA Methylation
New benchmarking study published in PLOS ONE shows Diagenode’s MethylCap Kit as best overall methyl binding domain kit for MBD-seq.
Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, was recently cited for having the overall best methyl binding domain (MBD)-based kit in a benchmarking study of five commercially-available MBD-based kits designed to study genome-wide DNA methylation patterns. Aberrant DNA methylation has been associated with various diseases, including most cancers, cardiovascular disease, and Alzheimer's disease, highlighting the significance of the evaluation. Additionally, recent research shows that MBD-based sequencing is the most cost-efficient method for genome wide DNA methylation profiling.